Dr Brendan Jenkins
Brendan’s research involves stomach (gastric) cancers which is the second most common cause of cancer related deaths worldwide, and represents a growing number of cancers, including liver, prostate & colon, associated with chronic inflammation. The mechanisms by which inflammation can lead to cancer are poorly understood. Brendan’s research has discovered that blocking the signalling pathways of a particular protein (STAT3) inside stomach cells can prevent inflammation and tumour formation in pre-clinical mouse models of gastric cancer.
Brendan has been successful in establishing a broad network of basic science and clinical collaborators.